Indocyanine Green Fluorescence Imaging to Predict Graft Survival After Orthotopic Liver Transplantation: A Pilot Study

Damien Dousse, Eric Vibert, Quentin Nicolas, Muga Terasawa, Luis Cano, Marc‐Antoine Allard, Chady Salloum, Oriana Ciacio, Gabriella Pittau, Antonio Sa Cunha, Daniel Cherqui, René Adam, Didier Samuel, Irene Vignon‐Clementel, Nicolas Golse – 13 May 2020 – The incidence of primary nonfunction (PNF) after liver transplantation (LT) remains a major concern with the increasing use of marginal grafts. Indocyanine green (ICG) fluorescence is an imaging technique used in hepatobiliary surgery and LT.

Livers From Pediatric Donation After Circulatory Death Donors Represent a Viable and Underutilized Source of Allograft

Christopher J. Little, Andre A. S. Dick, James D. Perkins, Evelyn K. Hsu, Jorge D. Reyes – 13 May 2020 – Despite increased numbers of donation after circulatory death (DCD) donors, pediatric DCD livers are underused. To investigate possible reasons for this discrepancy, we conducted a retrospective cohort study using 2 data sets from the Organ Procurement and Transplantation Network for all deceased liver donors and for all recipients of DCD liver transplants from March 8, 1993, to June 30, 2018.

Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates

Hilary M. DuBrock, Michael J. Krowka, Karen Krok, Kimberly Forde, Carl Mottram, Paul Scanlon, Nadine Al‐Naamani, Mamta Patel, Amber McCormick, Michael B. Fallon, Steven M. Kawut – 11 May 2020 – We investigated the prevalence of spirometric restriction in liver transplantation (LT) candidates and the clinical impacts of restriction. We performed a cross‐sectional study within the Pulmonary Vascular Complications of Liver Disease 2 (PVCLD2) study, a multicenter prospective cohort study of patients being evaluated for LT.

Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies

Xinjun Lu, Panagiotis Paliogiannis, Diego F. Calvisi, Xin Chen – 11 May 2020 – Primary liver cancers, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), are highly lethal tumors, with high worldwide frequency and few effective treatment options. The mammalian target of rapamycin (mTOR) complex is a central regulator of cell growth and metabolism that integrates inputs from amino acids, nutrients, and extracellular signals. The mTOR protein is incorporated into two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).

The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications

Gregory Dean, Stephen Hanauer, Josh Levitsky – 11 May 2020 – The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary tract disease without approved medical therapy, is not well understood. The relationship between PSC and inflammatory bowel disease has inspired theories that intestinal factors may contribute to the development and progression of hepatobiliary fibrosis in PSC. There is evidence from both fecal and mucosa‐associated microbial studies that patients with PSC harbor an abnormal enteric microbiome.

Left Hepatic Vein Preferential Approach Based on Anatomy Is Safe and Feasible for Laparoscopic Living Donor Left Lateral Sectionectomy

Lu Lu, Zheng‐Xin Wang, Wen‐Wei Zhu, Cong‐Huan Shen, Yi‐Feng Tao, Zhen‐Yu Ma, Quan‐Bao Zhang, Rui‐Dong Li, Hu‐Liang Jia, Lun‐Xiu Qin, Jin‐Hong Chen – 11 May 2020 – We assess the safety and feasibility of the left hepatic vein preferential approach (LHVPA) based on left hepatic vein (LHV) anatomy for living donor laparoscopic left lateral sectionectomy (LLLS). Data from 50 donors who underwent LLLS in Huashan Hospital from October 2016 to November 2019 were analyzed retrospectively.

The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications

Gregory Dean, Stephen Hanauer, Josh Levitsky – 11 May 2020 – The pathogenesis of primary sclerosing cholangitis (PSC), a progressive biliary tract disease without approved medical therapy, is not well understood. The relationship between PSC and inflammatory bowel disease has inspired theories that intestinal factors may contribute to the development and progression of hepatobiliary fibrosis in PSC. There is evidence from both fecal and mucosa‐associated microbial studies that patients with PSC harbor an abnormal enteric microbiome.

Subscribe to